ATEZOLIZUMAB ( ROCHE ) FRACASA EN FASE III CÁNCER DE PULMÓN MICROCÍTICO EN ESTADIO LIMITADO .CHEMORADIATION ± ATEZOLIZUMAB IN LIMITED-STAGE SMALL CELL LUNG CANCER : RESULTS OF PHASE III OF NRG ONCÓLOGY / ALLIANCE LU005 .

13 ENERO 2026 .

Results :

Patients Were Randomly Assigned From May 2019 To December 2023 .

The MEDIAN OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + ATEZOLIZUMAB arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]) .

 The Median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + ATEZOLIZUMAB arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]) .

 The Median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + ATEZOLIZUMAB arm (HR, 0.96 [95% CI, 0.76 to 1.21]) .

No unexpected safety signals with concurrent ATEZOLIZUMAB were observed .

CONCLUSIÓN :

CONCURRENT AND ADJUVANT ATEZOLIZUMAB WITH CHEMORADIATION DID NOT IMPROVE SURVIVAL IN PATIENTS WITH LS-SCLC .